HIM
SUPN icon

Hillsdale Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Hillsdale Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-180
Closed -$5.89K – 708
2025
Q1 		$5.89K Buy
+180
New +$6.38K ﹤0.01% 558

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Hillsdale Investment Management's SUPN Position: Q2 2025 in Review

Hillsdale Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 180 shares — an estimated $5.89K sold.

Hillsdale Investment Management first reported a position in SUPN in Q1 2025 and held it in 1 quarter. The position peaked at $5.89K in Q1 2025. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

  • Hillsdale Investment Management reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hillsdale Investment Management sold 180 Supernus Pharmaceuticals shares in Q2 2025, an estimated $5.89K.
  • Hillsdale Investment Management first reported a position in Supernus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Hillsdale Investment Management's Supernus Pharmaceuticals position peaked at $5.89K in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on Hillsdale Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.